Page last updated: 2024-11-02

pioglitazone and Pneumonia

pioglitazone has been researched along with Pneumonia in 5 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Pneumonia: Infection of the lung often accompanied by inflammation.

Research Excerpts

ExcerptRelevanceReference
"Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo."9.22Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. ( Anderson, JR; Bailey, H; Harrison, TW; Hodgson, DB; Knox, AJ; Mortimer, K; Pang, L; Shaw, DE; Smith, KM, 2016)
"Pioglitazone treatment was associated with increased expression of chemokine (Cxcl1, Cxcl2, and Ccl20) and cytokine genes (Tnfa, Il6, and Cfs3) in bronchial brushes obtained 6 h after infection."5.72The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia. ( de Vos, AF; Ferreira, BL; Otto, NA; Ramirez-Moral, I; Salomão, R; van der Poll, T, 2022)
"Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo."5.22Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. ( Anderson, JR; Bailey, H; Harrison, TW; Hodgson, DB; Knox, AJ; Mortimer, K; Pang, L; Shaw, DE; Smith, KM, 2016)
"Pioglitazone treatment was associated with increased expression of chemokine (Cxcl1, Cxcl2, and Ccl20) and cytokine genes (Tnfa, Il6, and Cfs3) in bronchial brushes obtained 6 h after infection."1.72The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia. ( de Vos, AF; Ferreira, BL; Otto, NA; Ramirez-Moral, I; Salomão, R; van der Poll, T, 2022)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Ferreira, BL1
Ramirez-Moral, I1
Otto, NA1
Salomão, R1
de Vos, AF1
van der Poll, T1
Malekinejad, H1
Khoramjouy, M1
Hobbenaghi, R1
Amniattalab, A1
Anderson, JR1
Mortimer, K1
Pang, L1
Smith, KM1
Bailey, H1
Hodgson, DB1
Shaw, DE1
Knox, AJ1
Harrison, TW1
Sharma, R1
Kaundal, RK1
Sharma, SS1
Rydén, L1
Thráinsdóttir, I1
Swedberg, K1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
PPAR-gamma: a Novel Therapeutic Target in Asthma?[NCT01134835]Phase 468 participants (Actual)Interventional2010-06-30Terminated (stopped due to safety concerns with pioglitazone)
PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993]Phase 34,373 participants (Actual)Interventional2001-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for pioglitazone and Pneumonia

ArticleYear
Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.
    PloS one, 2016, Volume: 11, Issue:8

    Topics: Adult; Aged; Asthma; Chemokine CCL2; Chemokine CXCL10; Double-Blind Method; Eosinophil Cationic Prot

2016

Other Studies

4 other studies available for pioglitazone and Pneumonia

ArticleYear
The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia.
    Clinical and experimental immunology, 2022, 05-12, Volume: 207, Issue:3

    Topics: Animals; Epithelial Cells; Hypoglycemic Agents; Inflammation; Mice; Pioglitazone; Pneumonia; PPAR ga

2022
Atorvastatin attenuates the paraquat-induced pulmonary inflammation via PPARγ receptors: a new indication for atorvastatin.
    Pesticide biochemistry and physiology, 2014, Volume: 114

    Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Heptanoic Acids; Herbicides; Interleukin-6; Lung; M

2014
Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs.
    Pulmonary pharmacology & therapeutics, 2009, Volume: 22, Issue:3

    Topics: Administration, Inhalation; Animals; Bronchoalveolar Lavage Fluid; Escherichia coli Proteins; Guinea

2009
Adjudication of serious heart failure in patients from PROactive.
    Lancet (London, England), 2007, Jan-20, Volume: 369, Issue:9557

    Topics: Heart Failure; Hospital Mortality; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Pneum

2007